Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Larimar Therapeutics Inc’s stock clocked out at $2.65, down -7.99% from its previous closing price of $2.88. In other words, the price has decreased by -$7.99 from its previous closing price. On the day, 1.27 million shares were traded.
Ratios:
To gain a deeper understanding of LRMR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.10 and its Current Ratio is at 13.10. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Truist on January 29, 2025, initiated with a Buy rating and assigned the stock a target price of $18.
On October 16, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $26.
On October 03, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $22.Wedbush initiated its Outperform rating on October 03, 2024, with a $22 target price.
Stock Price History:
Over the past 52 weeks, LRMR has reached a high of $11.20, while it has fallen to a 52-week low of $2.52. The 50-Day Moving Average of the stock is -22.61%, while the 200-Day Moving Average is calculated to be -59.45%.
Shares Statistics:
A total of 63.81M shares are outstanding, with a floating share count of 36.46M. Insiders hold about 42.86% of the company’s shares, while institutions hold 59.26% stake in the company.
